First human trial tests new drug targeting a specific cancer weakness
NCT ID NCT07128303
Summary
This is an early-stage study to find a safe dose and understand the side effects of a new drug called GS-5319. It is for adults with advanced solid tumors that have stopped responding to standard treatments and have a specific genetic alteration called MTAP-deletion. The main goal is to see how well people tolerate the drug and to determine the best dose for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
START - Centro Oncológico Clara Campal
RECRUITINGMadrid, 28050, Spain
-
START Madrid - FJD - Hospital Fundación Jiménez Díaz - Phase I Clinical Trials Unit
RECRUITINGMadrid, 28040, Spain
-
START San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Vall d'Hebron Institute of Oncology (VHIO)
RECRUITINGBarcelona, 08035, Spain
Conditions
Explore the condition pages connected to this study.